Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
August 2015, Vol 6, No 7
August 2015, Vol 6, No 7
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
By
Lisa A. Raedler, PhD, RPh
Drug Updates
August 2015, Vol 6, No 7
The National Cancer Institute estimates that 231,840 American women will be diagnosed with breast cancer, and nearly 40,300 women will die from the disease in 2015. Overall, 61% of women with breast cancer are diagnosed while the disease is confined to the breast; for these women, the 5-year survival rate is 98.6%. However, for women with metastatic breast cancer, the 5-year survival rate falls sharply, to 26%.
Read Article
Personalized Medicine Affordability Lies in Enhanced Predictors of Response to Therapy
By
Wayne Kuznar
Personalized Medicine
August 2015, Vol 6, No 7
Washington, DC—Personalized medicine is the best way to take advantage of innovation in therapy, but the method in which it is paid for must be addressed to fully realize its potential, said Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
High-Value Narrow Networks and Patient Safety Organizations the Future of Cancer Care
By
Wayne Kuznar
August 2015, Vol 6, No 7
Washington, DC—Emerging trends in oncology care management include economic transparency, high-value narrow networks (now also referred to as “power networks”), patient–provider profile matching, and an evolving role for risk management. Narrow networks have been shown to lower overall costs and premiums, reduce care variation, and increase patient outcomes and satisfaction, said Grant D. Lawless, RPh, MD, Associate Professor, Clinical Pharmacy and Economics, University of Southern California, Los Angeles, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Combination of PARP and PI3K Inhibitors Share a Genomic Landscape in Breast and Ovarian Cancers
By
Phoebe Starr
Personalized Medicine
August 2015, Vol 6, No 7
Philadelphia, PA—Now that a number of targeted therapies are available for the treatment of cancer, one of the big questions is how to best combine them, especially for patients with few other good treatment options.
Read Article
Cell Surface Amino Acid Potential as Prostate Cancer Biomarker
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
August 2015, Vol 6, No 7
New Orleans, LA—Prostate cancer may soon have a new biomarker. The cell surface amino acid glypican-1 (GPC-1) was shown in a pilot study to have specificity of 70% for prostate cancer with a sensitivity of >30%, said Jonathan Henderson, MD, a urologist at Regional Urology in Shreveport, LA, at the 2015 American Urological Association meeting.
Read Article
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
Emerging Therapies
,
Personalized Medicine
August 2015, Vol 6, No 7
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease. The study appeared online July 20, 2015, in
Nature Medicine
.
Read Article
GADOLIN Trial: Obinutuzumab an Effective Treatment for Indolent Lymphoma
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
August 2015, Vol 6, No 7
Chicago, IL—The results of the phase 3 GADOLIN trial provide the first proof of efficacy for obinutuzumab (Gazyva) in patients with indolent non-Hodgkin lymphoma (NHL). Obinutuzumab added to standard bendamustine (Treanda) chemotherapy almost doubled progression-free survival (PFS) in patients with rituximab (Rituximab)-refractory indolent lymphoma—the median PFS was 29.2 months with obinutuzumab plus bendamustine versus 14 months with bendamustine alone.
Read Article
Value-Based Strategies for Patients with Multiple Myeloma
By
Phoebe Starr
Hematologic Malignancies
,
Multiple Myeloma
,
Value-Based Care
August 2015, Vol 6, No 7
At the Fifth Annual Conference of the Association for Value-Based Cancer Care in Washington, DC, Grant Lawless, RPh, MD, FACP, of the University of Southern California, Los Angeles, moderated a multidisciplinary panel on value-based care for patients with multiple myeloma.
Read Article
Assessing the Cost-Effectiveness of Necitumumab in Squamous-Cell Lung Cancer
By
Dana Taylor
Economics & Value
,
Economics of Cancer Care
August 2015, Vol 6, No 7
Chicago, IL—An economic analysis presented by Daniel Goldstein, MD, of Emory University, Atlanta, GA, at the 2015 American Society of Clinical Oncology meeting, was conducted to see at what price will necitumumab (which is currently being reviewed by the FDA for use in metastatic squamous-cell lung cancer) be cost-effective. According to this analysis, necitumumab will have to be priced at less than $1300 per cycle to be cost-effective based on the accepted willingness-to-pay threshold of $150,000.
Read Article
A Patient’s Perception of Value in Cancer Treatment Today
By
Marion Toby Koch
Patient Perspective
,
Value Peer-spectives
August 2015, Vol 6, No 7
Science and technology have taken us through a dynamic portal, transforming medicine into a business and cancer into an industry that is challenged by its clinical benefits, safety, and cost-effectiveness. We are now witnessing a change in oncology with the migration from doctor- to patient-centric treatment.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma